https://obliquet.com/ 2023-12-05T07:46:42+00:00 https://obliquet.com/corporate-governance/foretradesemission-2023/ 2024-02-16T10:44:11+00:00 https://obliquet.com/rights-issue-2024/ 2024-10-08T12:05:06+00:00 https://obliquet.com/foretradesemission-2025/ 2025-08-25T08:48:16+00:00 https://obliquet.com/partnerships/ 2024-05-23T10:05:48+00:00 https://obliquet.com/board-of-directors/ 2025-07-03T07:17:05+00:00 https://obliquet.com/corporate-governance/annual-general-meeting-2022/ 2022-06-23T12:35:29+00:00 https://obliquet.com/investor-relations/foretradesemission-av-tvingande-konvertibler-2022/ 2024-02-16T10:48:37+00:00 https://obliquet.com/partnerships-2/ 2024-05-23T10:04:28+00:00 https://obliquet.com/fincancial-reports/ 2025-08-28T07:23:02+00:00 https://obliquet.com/disclaimer/ 2021-09-30T12:42:35+00:00 https://obliquet.com/contact/ 2026-01-23T13:11:46+00:00 https://obliquet.com/press-releases/ 2025-07-07T12:22:08+00:00 https://obliquet.com/previous-general-meetings/ 2025-05-26T12:48:28+00:00 https://obliquet.com/board-of-directors-and-management/ 2025-07-09T06:42:41+00:00 https://obliquet.com/annual-reports/ 2025-05-07T13:10:32+00:00 https://obliquet.com/portfolio/ 2023-11-07T08:18:18+00:00 https://obliquet.com/abiprot-antibody-platform/ 2024-06-26T11:45:07+00:00 https://obliquet.com/about-us/idea-and-vision/ 2024-06-26T11:43:10+00:00 https://obliquet.com/privacy-policy/ 2021-10-02T06:30:32+00:00 https://obliquet.com/news/oblique-therapeutics-business-update/ 2024-12-18T12:17:21+00:00 https://obliquet.com/news/https-obliquet-com-wp-content-uploads-2024-12-animal-health-company-news-pdf/ 2024-12-09T12:09:29+00:00 https://obliquet.com/news/oblique-therapeutics-enters-a-research-agreement-with-eli-lilly-and-company/ 2024-08-27T12:23:23+00:00 https://obliquet.com/news/oblique-therapeutics-and-kth-enters-a-strategic-collaboration/ 2024-06-18T15:20:03+00:00 https://obliquet.com/news/2378/ 2024-01-23T16:30:41+00:00 https://obliquet.com/news/oblique-therapeutics-forms-strategic-collaboration-with-aax-biotech/ 2023-11-28T11:25:16+00:00 https://obliquet.com/news/oblique-therapeutics-enters-an-agreement-with-a-large-us-based-pharmaceutical-company/ 2023-11-17T10:53:09+00:00 https://obliquet.com/news/oblique-therapeutics-presenterar-pa-redeye-neurology-theme-event-october-11-at-redeye/ 2024-01-23T11:48:35+00:00 https://obliquet.com/news/report-launch-the-swedish-drug-discovery-and-development-pipeline-202/ 2023-03-08T09:10:10+00:00 https://obliquet.com/news/oblique-therapeutics-offentliggor-utfall-i-genomford-foretradesemission/ 2023-02-15T16:00:03+00:00 https://obliquet.com/news/oblique-therapeutics-is-pleased-to-be-participating-in-the-biotechgate-digital-partnering-event/ 2023-01-30T10:30:20+00:00 https://obliquet.com/news/announcement-of-oblique-therapeutics-s-rights-issue-2023/ 2023-01-13T11:26:36+00:00 https://obliquet.com/news/oblique-therapeutics-is-thrilled-to-be-attending-in-person-at-the-41st-annual-j-p-morgan-healthcare-conference/ 2023-01-13T13:56:06+00:00 https://obliquet.com/news/oblique-therapeutics-is-thrilled-to-take-part-digitally-to-the-next-bio-partnering-jpm-week-january-9-12-2023/ 2022-12-22T19:41:08+00:00 https://obliquet.com/news/oblique-therapeutics-is-thrilled-to-take-part-to-the-next-plcf-event-in-france/ 2022-11-30T08:13:36+00:00 https://obliquet.com/news/oblique-therapeutics-is-excited-to-be-participating-in-the-biotechgate-digital-partnering-event/ 2022-11-23T07:53:06+00:00 https://obliquet.com/news/oblique-therapeutics-takes-part-to-the-11th-drud-discovery-strategic-summit/ 2022-11-11T09:01:48+00:00 https://obliquet.com/news/oblique-therapeutics-is-pleased-to-announce-the-nomination-of-christer-nordstedt-m-d-phd-as-chief-executive-officer/ 2022-11-09T08:58:05+00:00 https://obliquet.com/news/looking-forward-to-attend-in-person-the-bio-europe-meeting-october-24-26-2022-in-leipzig-germany/ 2022-10-18T11:19:52+00:00 https://obliquet.com/news/oblique-therapeutics-will-be-participating-virtually-in-bio-japan-2022/ 2022-10-10T09:32:52+00:00 https://obliquet.com/news/oblique-therapeutics-is-attending-to-biopharma-usa-boston/ 2022-10-10T09:28:08+00:00 https://obliquet.com/news/oblique-therapeutics-will-take-part-to-the-upcoming-biotechgate-digital-partnering/ 2022-10-10T09:27:00+00:00 https://obliquet.com/news/oblique-therapeutics-ab-rekrytering-av-ny-vd/ 2022-08-02T13:38:43+00:00 https://obliquet.com/news/north-point-securities-agerade-finansiell-radgivare-i-samband-med/ 2022-07-08T07:32:44+00:00 https://obliquet.com/news/oblique-therapeutics-offentliggor-utfall-i-foretradesemission-av-tvingande-konvertibler/ 2022-07-01T14:49:23+00:00 https://obliquet.com/news/protocol-from-the-annual-general-meeting-15th-june-2022/ 2022-06-23T12:46:28+00:00 https://obliquet.com/news/kommunike-fran-arsstamma-2022-oblique-therapeutics/ 2022-06-15T15:37:09+00:00 https://obliquet.com/news/just-out-oblique-therapeutics-ab-annual-report-for-2021/ 2022-06-02T13:47:33+00:00 https://obliquet.com/news/follow-us-on-linkedin/ 2022-05-27T08:34:55+00:00 https://obliquet.com/news/oblique-therapeutics-ab-forlanger-teckningsperiod/ 2022-05-20T12:24:54+00:00 https://obliquet.com/news/oblique-therapeutics-ab-publ-will-be-participating/ 2022-05-20T10:22:08+00:00 https://obliquet.com/news/oblique-therapeutics-ab-publ-will-be-at-the-pharma-partnering-summit/ 2022-03-14T07:59:11+00:00 https://obliquet.com/news/thrilled-to-take-part-a-expert-speaker-to-the-next-ddn-event/ 2022-03-08T08:07:43+00:00 https://obliquet.com/news/oblique-therapeutics-ab-publ-will-be-attending/ 2022-02-28T06:46:00+00:00 https://obliquet.com/news/we-are-hiring-laboratory-engineer/ 2022-02-04T10:53:44+00:00 https://obliquet.com/news/oblique-therapeutics-will-join-the-biotechgate-digital-partnering/ 2022-03-04T16:26:05+00:00 https://obliquet.com/news/oblique-therapeutics-is-pleased-to-announce-that-the-united-states-patent-and-trademark-office/ 2022-03-04T16:26:41+00:00 https://obliquet.com/news/obliques-presentation-at-the-virtual-j-p-morgan-healthcare-conference/ 2022-03-04T16:27:06+00:00 https://obliquet.com/news/top-immunotherapy-solution/ 2022-03-04T16:27:42+00:00 https://obliquet.com/news/oblique-therapeutics-interim-report-for/ 2022-03-04T16:27:58+00:00 https://obliquet.com/news/oblique-will-be-at-the-3rd-ras-mapk-pathway-targeted-drug-discovery-summit/ 2022-03-04T16:28:24+00:00 https://obliquet.com/news/oblique-therapeutics-welcomes-cecilia-larsson/ 2022-03-04T16:29:04+00:00 https://obliquet.com/news/oblique-therapeutics-welcomes-mats-lindskog/ 2022-03-04T16:29:26+00:00 https://obliquet.com/news/oblique-therapeutics-presents-its-anti-thioredoxin-mab-program/ 2022-03-04T16:29:53+00:00 https://obliquet.com/news/new-press-article-svenska-dagbladet/ 2021-10-13T08:42:27+00:00 https://obliquet.com/news/congratulations-to-david-julius-ph-d-jointly-with-ardem-patapoutian-who-have-won-the-2021-nobel-prize-in-physiology-or-medicine-for-their-discoveries-of-receptors-for-temperature-and-touch/ 2021-10-12T12:12:31+00:00 https://obliquet.com/news/oblique-therapeutics-announces-that-it-has-reached-a-key-milestone/ 2022-01-26T07:58:39+00:00 https://obliquet.com/news/oblique-therapeutics-one-of-the-101-top/ 2022-01-26T07:59:11+00:00 https://obliquet.com/news/have-you-missed-obliques-presentation/ 2021-09-22T15:54:33+00:00 https://obliquet.com/news/our-founder-ceo-prof-owe-orwar-has-been-named-a-winner/ 2021-09-22T17:35:40+00:00 https://obliquet.com/news/for-the-1st-neuropathic-pain-therapeutics-summit/ 2021-10-04T14:37:12+00:00 https://obliquet.com/news/on-wednesday-the-15th-of-june-2021/ 2021-10-04T13:29:29+00:00 https://obliquet.com/programs/atrpv1_intended-for-treatment-of-pain/ 2023-06-02T07:55:33+00:00 https://obliquet.com/news/the-prestigious-shanghai-ranking-gives-at-karolinska-institutet/ 2021-09-22T18:22:30+00:00 https://obliquet.com/news/science-advances-has-published-a-research-article/ 2021-09-22T18:41:11+00:00 https://obliquet.com/news/on-march-10th-2021-professor-owe-orwar-ceo/ 2021-09-22T18:08:07+00:00 https://obliquet.com/news/oblique-therapeutics-ab-raises-98-msek/ 2021-09-23T08:44:33+00:00 https://obliquet.com/news/this-is-our-first-abiprot-patent-we-hope-that-many-more-will-follow/ 2021-09-22T17:36:03+00:00 https://obliquet.com/news/oblique-therapeutics-ab-together-with-collaborators/ 2021-09-23T09:41:07+00:00 https://obliquet.com/news/24th-sept-2020-oblique-therapeutics/ 2021-09-23T09:41:30+00:00 https://obliquet.com/news/oblique-therapeutics-is-honored-to-participate/ 2021-09-23T09:20:05+00:00 https://obliquet.com/news/oblique-therapeutics-and-targovax-enter-collaboration/ 2021-09-23T09:31:49+00:00 https://obliquet.com/news/oblique-therapeutics-ab-has-identified/ 2021-09-23T09:39:50+00:00 https://obliquet.com/news/general-meeting-2020/ 2021-09-23T09:52:09+00:00 https://obliquet.com/news/notice-convening-the-extraordinary/ 2021-09-23T09:58:28+00:00 https://obliquet.com/news/oblique-will-be-presenting-at-the-ras-targeted/ 2021-09-23T10:10:36+00:00 https://obliquet.com/news/oblique-therapeutics-is-on-eu-startups-top-10-list/ 2021-09-23T10:16:12+00:00 https://obliquet.com/news/we-are-proud-to-have-been-recognised/ 2021-09-23T10:26:13+00:00